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Abstract: Six classes of coumarin derivatives (i.e. 3-alkyl-4-methylcoumarins, pyranocoumarins, 
coumarin carboxamides, quaternary ammonium coumarins, 7-aminocoumarins, and 4-aminocoumarins) 
were synthesized and evaluated for inhibition of cell proliferation of colon adenocarcinoma (HT-29), 
breast carcinoma (MDA-MB-468 or MCF-7), and human ovarian adenocarcinoma (SK-OV-3) cells. C-
3-Alkyl substituted analogs of 4-methylcoumarins and pyranocoumarins, 5 and 6, inhibited the cell 
proliferation of MDA-MB-468 and SK-OV-3 cells by 53-74%, while 3-decyl substituted 
pyranocoumarin 10 and triethyl substituted quaternary ammonium coumarin derivative 29 inhibited the 
cell proliferation of HT-29 and SK-OV-3 cells by 63-72% at a concentration of 50 µM. Among all the 
compounds studied, C-3 decyl substituted quaternary ammonium coumarin derivative 25 exhibited the 
highest Src kinase inhibition with an IC50 value of 21.6 µM. 
 
 
Introduction 
 
Cancer is the second leading cause of death 
worldwide, following heart diseases. World 
Health Organization has estimated over 11 
million global deaths due to cancer in 2030 
[1]. According to the American Cancer 
Society, about 1.5 million new cancer cases 
and more than 500,000 deaths have occurred 
due to cancer in USA alone in 2009 [2]. 
 
The reduction in mortality and morbidity  
------------------------------------------------------ 
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has been achieved among cancer patients 
through use of current chemotherapeutic 
agents. Most drugs currently available for 
treatment of cancer are mechanistically 
based on inhibition of cell proliferation and 
induction of apoptosis. However, the 
application of many antiproliferative drugs 
is associated to high toxicity due to their 
mechanisms of action and non-specific 
targeting. For example, cardiovascular side 
effects are common with antimetabolites 
and the anti-angiogenic agents. Furthermore, 
multi-drug resistance has become one of the 
major challenges to encounter in cancer 
chemotherapy. Statistically half of all cancer 
patients either fail to respond or will relapse 
from the initial response and ultimately die 
from their metastatic disease [3]. Thus, the 
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continued commitment to the arduous tasks 
involved in the discovery of new 
antiproliferative agents with less toxicity, 
higher efficacy, and better selectivity 
remains critically important. 
 
Extensive research during the past decade 
has focused on targeting tumors at 
molecular level and processes that are 
prerequisites for tumor growth. For 
example, angiogenesis has spurred an 
intensive interest in the last decade of the 
twentieth century. Metastasis is a closely 
related process to angiogenesis, and thus has 
also become a focus of contemporary cancer 
drug discovery. Recent major advances in 
cancer therapy have been seen in the area of 
protein kinases, which represent one of the 
largest protein families [4]. Phosphorylation 
of many protein substrates occurs in the 
presence of protein tyrosine kinases (PTKs) 
that catalyze the transfer of γ-phosphate 
group from ATP to specific tyrosine 
residues. PTKs have critical roles in the 
signal transduction pathways. Extensive 
knowledge on PTKs has offered some of the 
most important targets such as HER-2, Flk-
1/KDR (VEGFR-2), Bcr-Abl, EGFR, and 
Src kinases for antiproliferative drug design 
[4]. 
 
Src kinase (Src), a prototype member of the 
Src family of kinases (SFKs) is over-
expressed in several types of human tumors 
including colon, breast, ovary, prostate, 
lung, and pancreas, and increased Src 
activity is observed in metastatic tumors 
[5,6]. Another key role of Src is the 
regulation of specific angiogenic factors that 
promote tumor progression. Studies 
demonstrated that this tyrosine kinase 
regulates both constitutive and growth 
factor-induced VEGF and IL-8 expression 
[7]. Recently our group studied the Src 
kinase inhibitory and antiproliferative 
activity of 3-phenylpyrazolopyrimidine-
1,2,3-triazole conjugates [8], 1-substituted 
3-(N-alkyl-N-phenylamino)propane-2-ols 
[9], and 4-aryl-4H-chromene-3-carbonitrile 
derivatives [10]. Furthermore, owing to the 
importance of Src kinase in cancer cell 
invasion and metastasis, there is a greater 
need to identify other small-molecules, 
scaffolds, or pharmacophore fragments as 
inhibitors. 
 
Coumarins comprise a vast array of 
biologically active compounds ubiquitous in 
plants, many of which have been used in 
traditional medicine since ancient times. The 
antitumor activity of coumarin against 
human tumor cell lines was first noted by 
Weber et al. [11]. The selective tumor cell-
specific cytotoxicity of coumarins has been 
well documented by Riveiro et al. [12]. 
However, the use of coumarin in cancer 
chemotherapy was first established by the 
successful application of Warfarin sodium 
on V2 cancer cell, granulocytes, 
lymphocytes and macrophages in different 
animal models. Later, clinical trials 
demonstrated activity of coumarins in many 
different cancers, including prostate cancer, 
malignant melanoma and metastatic renal 
cell carcinoma [13]. In continuation of our 
efforts to design new antiproliferative agents 
[4,8-10,14-19], herein we report the 
synthesis of an array of six classes of 
coumarin derivatives (Figure 1) and 
evaluation of antiproliferative activities for 
establishing the structure-activity 
relationships. Further, to decipher the 
mechanism of antiproliferative activities of 
the compounds, the Src kinase inhibitory 
activities of the compounds were 
investigated. 
 
Materials and methods 
 
Chemistry 
 
The organic solvents were dried and 
distilled prior to their use. Reactions were 
monitored by precoated TLC plates (Merck 
silica gel 60F254); the spots were visualized 
either by UV light, or by spraying with 5% 
alcoholic FeCl3 solution. Silica gel (100-200 
mesh) was used for column 
chromatography. All the chemicals and 
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reagents were procured from Spectrochem 
Pvt. Ltd., India and Sigma-Aldrich 
Chemicals Pvt. Ltd., USA. Melting points 
were recorded in capillaries in suphuric acid 
bath and are uncorrected. Infrared spectra 
were recorded on Perkin-Elmer FT-IR 
model 9 spectrophotometer. The 1H and 13C 
NMR spectra were recorded on Jeol-400 
(400 MHz, 100.6 MHz) NMR spectrometer 
and Avance-300 (300 MHz, 75.5 MHz) 
spectrometer using TMS as internal 
standard. The chemical shift values are on δ 
scale and the coupling constant values (J) 
are in Hz. The HRMS data were recorded on 
Agilent-6210 ES-TOF, JEOL JMX-SX-
102A and Waters LCT Micromass-KC455. 
 
General procedure for the synthesis of 10-
hydroxy-4,8,8-trimethyl-3-alkyl-7,8-
dihydropyrano[3,2-g]chromen-2(6H)-
ones (6-10). A mixture of 7,8-dihydroxy-3-
alkyl-4-methylcoumarin (1.0 g), p-
toluenesulfonic acid monohydrate (1 
equivalent), and 1.5 equivalents of 2-
methyl-3-buten-2-ol were taken in a round 
bottom flask along with toluene as a solvent 
and refluxed for 24 h. The progress of the 
reaction was monitored using TLC. On 
completion of the reaction, the solvent was 
removed in vacuo and the solid obtained 
was dissolved in chloroform (50 mL). The 
chloroform layer was washed first with 
sodium hydroxide solution (1N, 2 × 50 mL) 
and then with brine solution (20 mL). The 
organic layer was then dried over anhydrous 
sodium sulfate. The solvent was removed in 
vacuo in a rotary evaporator to give an oily 
residue, which was then crystallized from 
hexane. 
 
3-Ethyl-10-hydroxy-4,8,8-trimethyl-7,8-
dihydro-6H-pyrano[3,2-g]chromen-2-one 
(6). Melting point = 175-176 oC; UV 
(acetonitrile) λmax: 261 and 318 nm; IR 
(KBr) νmax: 3404 (OH), 1710 (CO) cm-1; 1H 
NMR (CDCl3, 300 MHz): δ 1.10 (t, 3H, J = 
7.3 Hz, -CH2CH3), 1.41 (s, 6H, 2 x H-1′), 
1.87 (t, 2H, J = 6.4 Hz, H-6),  2.36 (s, 3H, 
C-4 CH3), 2.66 (q, 2H,  J = 7.3 Hz, -
CH2CH3), 2.85 (t, 2H, J = 6.4 Hz, H-7), 5.65 
(brs, 1H, OH),  6.87 (s, 1H, H-5); 13C NMR 
(CDCl3, 75.5 MHz): δ 13.26 (-CH2CH3), 
14.66 (C-4 CH3), 20.96 (-CH2CH3), 22.22 
(C-6), 26.91 and 27.18 (2 x C-1′), 32.78 (C-
7), 76.68 (C-8), 113.98 and 114.80 (C-5 and 
C-12), 117.58 and 124.92 (C-3 and C-14), 
131.87 and 138.87 (C-10 and C-11), 143.36 
and 146.21 (C-4 and C-13), 161.39 (C-2); 
HRMS: Calculated for C17H20O4 [M + H]+ 
289.1395, found 289.1524. 
 
10-Hydroxy-4,8,8-trimethyl-3-propyl-7,8-
dihydro pyrano[3,2-g]chromen-2(6H)-one 
(7). Melting point = 132-134 oC; UV 
(MeOH) λmax: 264 and 328 nm; IR (KBr) 
νmax: IR (KBr) νmax:  3388 (OH), 1690 (CO) 
cm-1; 1H NMR (CDCl3, 300 MHz) : δ 0.98 
(t, 3H, J = 7.4 Hz, -CH2CH2CH3), 1.41 (s, 
6H, 2 x H-1′),1.49-1.62 (m, 2H, -
CH2CH2CH3), 1.87 (t, 2H, J = 6.6 Hz, H-6), 
2.35 (s, 3H, C-4 CH3), 2.61 (t, 2H, J = 7.8 
Hz, -CH2CH2CH3), 2.85 (t, 2H, J = 6.6 Hz, 
H-7), 5.62 (brs, 1H, OH),  6.87 (s, 1H, H-5); 
13C NMR (CDCl3, 75.5 MHz): δ 14.13 (-
CH2CH2CH3), 14.78 (C-4 CH3), 22.18 and 
22.65 (-CH2CH2CH3 and C-6), 24.32 (-
CH2CH2CH3), 26.87 (2 x C-1′), 32.54 (C-7), 
76.61 (C-8), 113.96 and 114.44 (C-5 and C-
12), 119.12 and 123.67 (C-3 and C-14), 
131.77 and 138.82 (C-10 and C-11), 143.22 
and 146.25 (C-4 and C-13), 161.40 (C-2); 
HRMS: Calculated for C18H22O4 [M + H]+ 
303.1552, found 303.1812. 
 
3-Hexyl-10-hydroxy-4,8,8-trimethyl-7,8-
dihydro-6H-pyrano[3,2-g]chromen-2-one 
(8). Melting point = 140-141 oC; UV 
(MeOH) λmax: 263 and 320 nm; IR (KBr) 
νmax: 3436 (OH), 1672 (CO) cm-1; 1H NMR 
(Acetone-d6, 500 MHz): δ 0.90 (t, 3H, J = 
6.9 Hz, -CH2(CH2)4CH3), 1.32-1.52 (m, 
14H, -CH2(CH2)4CH3 and 2 x H-1′), 1.88 (t, 
2H, J = 6.6 Hz, H-6),  2.39 (s, 3H, C-4 
CH3), 2.62 (t, 2H, J = 7.7 Hz, -
CH2(CH2)4CH3), 2.87 (t, 2H, J = 6.6 Hz, H-
7), 6.99 (s, 1H, H-5), 7.81 (brs, 1H, OH); 
13C NMR (Acetone-d6, 125.7 MHz): δ 19.02 
(-CH2(CH2)4CH3), 19.68 (C-4 CH3), 22.98 
(C-6), 26.79 (2 x C-1′), 27.44, 31.68, 34.05, 
34.21, 37.16 (-(CH2)5CH3), 38.05 (C-7), 
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81.04 (C-8), 119.60 and 120.42 (C-5 and C-
12), 123.04 and 128.72 (C-3 and C-14), 
138.29 (C-10), 144.99, 149.48 and 151.74 
(C-4, C-11 and C-13), 166.40 (C-2); HRMS: 
Calculated for C21H28O4 [M + H]+ 345.1988, 
found 345.2100. 
 
3-Heptyl-10-hydroxy-4,8,8-trimethyl-7,8-
dihydro-6H-pyrano[3,2-g]chromen-2-one 
(9). Melting point = 120-122 oC; UV 
(MeOH) λmax: 264 and 328 nm; IR (KBr) 
νmax: 3409 (OH), 1687 (CO) cm-1; 1H NMR 
(CDCl3, 300 MHz): δ 0.87 (t, 3H, J = 6.3 
Hz, -CH2(CH2)5CH3), 1.27-1.50 (m, 10H, -
CH2(CH2)5CH3), 1.41 (s, 6H, 2 x H-1′), 1.87 
(t, 2H, J = 6.6 Hz, H-6), 2.34 (s, 3H, C-4 
CH3), 2.62 (t, 2H, J = 7.2 Hz, -
CH2(CH2)5CH3), 2.85 (t, 2H, J = 6.6 Hz, H-
7), 5.64 (brs, 1H, OH), 6.87 (s, 1H, H-5); 
13C NMR (CDCl3, 75.5 MHz): δ 14.13 (-
CH2(CH2)5CH3), 14.92 (C-4 CH3), 22.18 
(C-6), 26.87 (2 x C-1′), 22.67 27.68, 28.92, 
29.24, 29.69, 31.88 (-(CH2)6CH3), 33.74 (C-
7), 80.61 (C-8), 114.12 and 117.44 (C-5 and 
C-12), 123.82 and 124.23 (C-3 and C-14), 
131.77 (C-10), 138.82, 143.23 and 146.24 
(C-4, C-11 and C-13), 161.40 (C-2); HRMS: 
Calculated for C22H30O4 [M + H]+ 359.2144, 
found 359.1708. 
 
3-Decyl-10-hydroxy-4,8,8-trimethyl-7,8-
dihydro-6H-pyrano[3,2-g]chromen-2-one 
(10) 
Melting point = 147-148 oC; UV (MeOH) 
λmax: 263 and 321 nm; IR (KBr) νmax: 3429 
(OH), 1672 (CO) cm-1; 1H NMR (Acetone-
d6, 500 MHz): δ 0.87 (t, 3H, J = 7.2 Hz, -
CH2(CH2)8CH3), 1.30-1.54 (m, 22H, -
CH2(CH2)8CH3 and  2 x H-1′), 2.06 (t, 2H, J 
= 6.6 Hz, H-6), 2.41 (s, 3H, C-4 CH3), 2.62-
2.64 (m, 4H, -CH2(CH2)8CH3 and H-7), 6.86 
(brs, 1H, OH), 7.15 (s, 1H, H-5); 13C NMR 
(Acetone-d6, 125.7 MHz): δ 13.83 (-
CH2(CH2)8CH3), 14.75 (C-4 CH3), 22.81 
(C-6), 29.01 (2 x C-1′), 27.53, 28.58, 29.16, 
29.32, 29.47, 29.54, 29.72, 29.78 and 29.82 
(-(CH2)9CH3), 32.11 (C-7), 76.71 (C-8), 
112.12 and 114.39 (C-5 and C-12), 115.89 
and 122.87 (C-3 and C-14), 131.93 (C-10), 
142.22, 147.07 and 147.98 (C-4, C-11 and 
C-13), 161.05 (C-2); HRMS: Calculated for 
C25H36O4 [M + H]+ 401.2647, found 
401.2701. 
 
General procedure for the synthesis of 
amino acid derivatives of coumarin-3-
carboxamide (14-17). To a stirred solution 
of carboxy coumarin (1.0 g, 31 mmol) in 
100 mL acetone, triethylamine (4.2 equiv.) 
and ethyl chloroformate (4 equiv.) were 
added at 0 oC in about 15 minutes. The 
reaction mixture was stirred for 1 h and then 
filtered. To the resulting filtrate, protected 
amino acid (1.1 equiv.) was added and then 
the reaction mixture was stirred for 24 h at 
room temperature. The acetone was distilled 
off and remaining mixture was dissolved in 
ethyl acetate, washed with sodium 
bicarbonate solution. The solvent was 
distilled off and the resultant compound was 
recrystallized with chloroform and ether. 
 
Methyl 2-(2-oxo-2H-chromene-3-
carboxamido)-3-phenylpropanoate (14). 
Melting point = 108-110 oC (Literature 
value = 105-107 oC) [20]; UV (MeOH) λmax: 
292 nm; IR (KBr) νmax: 3312 (NH), 2951, 
2923, 2868, 1750 (COO), 1726 (CO), 1656 
(CONH) cm-1; 1H NMR (CDCl3, 300 MHz): 
δ 3.13-3.31 (m, 2H, -CH2Ph), 3.74 (s, 3H, 
OCH3), 4.98 (q, 1H, J = 7.35 Hz, H-2), 
7.22-7.34 (m, 5H, C6H5), 7.36-7.40 (m, 2H, 
H-6' and H-8'), 7.63-7.68 (m, 2H, H-5' and 
H-7'), 8.84 (s, 1H, H-4'), 9.23 (d, 1H, J = 7.2 
Hz, NH); 13C NMR (CDCl3, 75.5 MHz): δ 
37.79 (-CH2Ph), 52.29 (OCH3), 54.19 (C-2), 
116.53 (C-8'), 117.79 and 118.35 (C-3' and 
C-10'), 125.19 (C-7'), 127.08 (C6H5), 128.56 
(C6H5), 129.14 (C6H5), 129.74 (C-6'), 
134.14 (C-5'), 135.82 (C6H5), 148.48 (C-4'), 
154.36 (C-9'), 160.97 and 161.20 (C-2' and 
C-11'), 171.39 (C-1); HRMS: Calculated for 
C20H17NO5 [M]+ 351.1107, found 351.7543. 
 
Methyl 2-(2-oxo-2H-chromene-3-
carboxamido)acetate (15). Melting point = 
195 oC (Literature value = 193-195 oC) [20]; 
UV (MeOH) λmax: 292 nm; IR (KBr) νmax: 
3326 (NH), 2936, 2739, 1748 (COO), 1709 
(CO), 1654 (CONH) cm-1; 1H NMR 
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(DMSO-d6, 400 MHz): δ 3.68 (s, 3H, 
OCH3), 4.15 (d, 2H, J = 4.5 Hz, H-2), 7.41-
7.47 (m, 1H, H-6'), 7.51 (d, 1H, J = 6.7 Hz, 
H-8'), 7.77 ( t, 1H, J = 6.2 Hz,  H-7'), 7.96 
(d, 1H, J = 6.3 Hz,  H-5'), 8.91(s, 1H, H-4'), 
9.08 (t, 1H, J = 4.1 Hz, NH); 13C NMR 
(DMSO-d6, 100.6 MHz): δ 45.31 (OCH3), 
51.91 (C-2), 116.19 (C-8'), 118.10 and 
118.39 (C-3' and C-10'), 125.21 (C-7'), 
130.45 (C-6'), 134.40 (C-5'), 148.24 (C-4'), 
154.02 (C-9'), 160.31 and 161.46 (C-2' and 
C-11'), 169.98 (C-1); HRMS: Calculated for 
C13H11NO5 [M+H]+ 262.0637, found 
262.0307. 
 
Methyl 4-methyl-2-(2-oxo-2H-chromen-3-
carboxamido)pentanoate (16). Melting 
point = 124-126 oC (Literature value =120-
122 oC) [20]; UV (MeOH) λmax: 292 nm; IR 
(KBr) νmax: 3353 (NH), 3052, 2928, 2854, 
1734 (COO), 1705 (CO), 1652 (CONH) cm-
1; 1H NMR (DMSO-d6, 400 MHz): δ 0.91-
0.94 (m, 6H, -CH2CH(CH3)2), 1.66-1.76 (m, 
3H, -CH2CH(CH3)2), 3.69 (s, 3H, OCH3), 
4.58-4.62 (m, 1H, H-2), 7.44-7.47 (m, 1H, 
H-6'), 7.52 (d, 1H, J = 6.7 Hz, H-8'), 7.69-
7.78 (m, 1H, H-7'), 7.99 (dd, 1H, J = 0.90 
and 6.2 Hz, H-5'), 8.87 (s, 1H, H-4'),  8.98 
(d, 1H, J = 6.1 Hz, NH); 13C NMR (DMSO-
d6, 100.6 MHz): δ 21.63 and 22.72 (-
CH2CH(CH3)2), 24.50 (-CH2CH(CH3)2), 
40.33 (-CH2CH(CH3)2),  50.85 (OCH3), 
52.23 (C-2), 116.27 (C-8'), 118.33 and 
118.43 (C-3' and C-10'), 125.29 (C-7'), 
130.44 (C-6'), 134.44 (C-5'), 148.13 (C-4'), 
154.01 (C-9'), 160.58 and 161.21 (C-2' and 
C-11'), 172.41 (C-1); HRMS: Calculated for 
C17H19NO5 [M]+ 317.1263, found 317.8474. 
 
Methyl 3-(2-oxo-2H-chromen-3-
carboxamido)propanoate (17). Melting 
point = 152-154 oC (Literature value =150-
152 oC) [20]; UV (MeOH) λmax: 290 nm; IR 
(KBr) νmax: 3352 (NH), 3052, 2927, 1733 
(COO), 1703 (CO), 1650 (CONH) cm-1; 1H 
NMR (DMSO-d6, 400 MHz): δ 2.62 (t, 2H, 
J = 5.2 Hz, H-2), 3.57 (q, 2H, J = 5.0 Hz, H-
3), 3.63 (s, 3H, OCH3), 7.44 (t, 1H, J = 6.0 
Hz, H-6'), 7.49 (d, 1H, J = 6.6 Hz, H-8'), 
7.75 (t, 1H, J = 6.0 Hz, H-7'), 7.98 (d, 1H, J 
= 6.0 Hz, H-5'), 8.87 (brs, 2H, H-4' and 
NH); 13C NMR (DMSO-d6, 100.6 MHz): δ 
33.37 (C-2), 35.02 (C-3), 51.45 (OCH3), 
116.08 (C-8'), 118.39 and 118.54 (C-3' and 
C-10'), 125.09 (C-7'), 130.27 (C-6'), 134.11 
(C-5'), 147.65 (C-4'), 153.85 (C-9'), 160.32 
and 161.06  (C-2' and C-11'), 171.94 (C-1); 
HRMS: Calculated for C14H13NO5 [M + H]+ 
276.0794, found 276.1454. 
 
General procedure for the synthesis of 
amino alkylamino derivatives of 
coumarin-3-carboxamide (18-21). To a 
solution of coumarin-3-carboxylic acids (1.0 
g), BOP reagent (1.0 equivalent) in 
acetonitrile (20 ml) was added 1.3 
equivalents of triethylamine. This was 
followed by the addition of a solution of t-
butyl aminoalkylcarbamates (1.0 equiv.) 
dissolved in chloroform (15 ml). The 
resulting mixture was stirred at room 
temperature for 10-12 h. The progress of 
reaction was monitored on TLC. On 
completion of the reaction saturated brine 
solution was added to quench the reaction 
followed by extraction with ethyl acetate (3 
x 20 ml). The ethyl acetate layer was then 
successively washed with 4% citric acid, 
water, 4% sodium bicarbonate solution, and 
water. The organic layer was dried over 
anhydrous sodium sulfate, and solvent was 
removed in vacuo at 40 °C to provide crude 
product. The crude product obtained was 
crystallized in chloroform-petroleum ether 
(1:10) to give Boc protected alkyl amino 
coumarin carboxamides. Deprotection of the 
Boc group was carried out by treating the 
coumarin carbamate with a mixture of 
TFA/DCM (1:1, 2 ml) at room temperature. 
The progress of reaction was monitored on 
TLC. On completion of the reaction the 
solvent was evaporated under reduced 
pressure. Further the residue was treated 
with sodium hydroxide solution (1N) to 
neutralize the excess of trifluoroacetic acid 
and to generate a free amino group. This 
was followed by extraction with 
dichloromethane. The organic phase was 
dried over anhydrous sodium sulfate and 
evaporated under reduced pressure. The 
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obtained residue was crystallized in 
methanol to give free amino analogs of 
coumarin carboxamide. 
 
N-(2-Aminoethyl)-2-oxo-2H-1-
benzopyran-3-carboxamide (18). Melting 
point = 320 oC [21]; UV (acetonitrile) λmax: 
298 and 332 nm; IR (KBr) νmax: 3328 (NH), 
1694 (CO), 1654 (CONH) cm-1; 1H NMR 
(CDCl3, 400 MHz): δ 3.14 (brm, 2H, H-2″), 
3.74 (t, 2H, J = 6.6 Hz, H-1″), 7.36-7.41 (m, 
2H, H-6 and H-8), 7.64-7.71 (m, 2H, H-5 
and H-7), 8.92 (brs, 1H, NHCO), 9.07 (s, 
1H, H-4); 13C NMR (CDCl3, 100.6 MHz): 
δC 29.79 (C-2″), 37.58 (C-1″), 116.73, 
118.55 and 118.73 (C-3, C-8 and C-10), 
125.33, 129.84 and 134.03 (C-5, C-6 and C-
7), 148.39 (C-4), 154.50 (C-9), 161.50 and 
162.02 (C-1′ and C-2); HRMS: Calculated 
for C12H12N2O3 [M]+. 232.0848, found 
232.7881. 
 
N-(4-Aminobutyl)-2-oxo-2H-1-
benzopyran-3-carboxamide (19). Melting 
point = 249 oC; UV (acetonitrile) λmax: 292 
and 326 nm; IR (KBr) νmax: 3313 (NH), 
1722 (CO), 1658 (CONH) cm-1; 1H NMR 
(DMSO-d6, 300 MHz): δ 1.62 (brs, 2H, H-
3″), 3.24 (brs, 4H, H-2″ and H-4″), 3.39 
(brs, 2H, H-1″), 7.43-7.49 (m, 2H, H-6 and 
H-8), 7.73 (t, 1H, J = 6.0 Hz, H-7), 7.95 (d, 
1H, J = 6.9 Hz, H-5), 8.66 (brs, 1H, 
NHCO), 8.82 (s, 1H, H-4); 13C NMR 
(CDCl3, 100.6 MHz): δ 29.52 (C-3″), 30.20 
(C-2″), 32.02 (C-4″), 37.31 (C-1″), 112.92, 
115.43 and 119.32 (C-3, C-8 and C-10), 
120.99 and 124.88 (C-5 and C-6), 146.85, 
148.14 and 148.52 (C-4, C-7 and C-9), 
160.89 and 162.13 (C-1′ and C-2); HRMS: 
Calculated for C14H16N2O3 [M]+. 260.1161, 
found 260.6169. 
 
N-(2-Aminoethyl)-8-methoxy-2-oxo-2H-1-
benzopyran-3-carboxamide (20). Melting 
point = > 320 oC; UV (acetonitrile) λmax: 
311 nm; IR (KBr) νmax: 3332 (NH), 1715 
(CO), 1657 (CONH) cm-1; 1H NMR (CDCl3, 
400 MHz): δ 3.18 (t, 2H, J = 5.5 Hz, H-2″), 
3.71 (t, 2H, J = 5.5 Hz, H-1″), 3.96 (s, 3H, 
OCH3), 7.34-7.40 (m, 3H, H-5, H-6 and H-
7), 8.83 (s, 1H, H-4); 13C NMR (CDCl3, 
100.6 MHz): δ 38.56 (C-2″), 40.86 (C-1″), 
56.92 (OCH3), 117.35, 118.41 and 119.22 
(C-3, C-5 and C-7), 122.17 and 126.48 (C-6 
and C-10), 145.29, 148.37 and 150.01 (C-4, 
C-8 and C-9), 162.19 and 165.08 (C-1′ and 
C-2); HRMS: Calculated for C13H14N2O4 
[M]+. 262.0954, found 262.4382. 
 
N-(4-Aminobutyl)-8-methoxy-2-oxo-2H-1-
benzopyran-3-carboxamide (21). Melting 
point = 304 oC; UV (acetonitrile) λmax: 310 
nm; IR (KBr) νmax: 3422 (NH), 2932, 1706 
(CO), 1658 (CONH) cm-1; 1H NMR (CDCl3, 
300 MHz): δ 1.60 (brs, 2H, H-3″), 3.35-3.36 
(m, 4H, H-2″ and H-4″), 3.83 (brs, 2H, H-
1″), 3.92 (s, 3H, OCH3), 7.31-7.41 (m, 2H, 
H-6 and H-7), 7.47 (d, 1H, J = 7.5 Hz, H-5), 
8.64 (brs, 1H, NHCO),  8.76 (s, 1H, H-4); 
13C NMR (CDCl3, 100.6 MHz): δ 25.92 (C-
3″), 27.35 (C-2″), 35.34 (C-4″), 38.81 (C-
1″), 56.82 (OCH3), 116.08, 117.24 and 
121.20 (C-3, C-5 and C-7), 122.17 and 
126.24 (C-6 and C-10), 144.46, 148.42 and 
149.59 (C-4, C-8 and C-9), 162.22 and 
163.87 (C-1′ and C-2); HRMS: Calculated 
for C15H18N2O4 [M]+. 290.1267, found 
290.9057. 
 
General procedure for the synthesis of 7-
aminocoumarins (30-34). Ethyl 
chloroformate (10.0 g, 92 mmol) was added 
in one portion to a stirred suspension of m-
aminophenol (10.0 g, 92 mmol) in 400 mL 
of anhydrous diethyl ether. A white 
precipitate (amine hydrochloride) formed 
immediately. The reaction mixture was 
stirred for additional 2 h at room 
temperature. The hydrochloride was 
removed by filtration. The filtrate was then 
evaporated to give grey colored solid. 
Further crystallization from petroleum ether 
(200 mL) gave upon cooling (0 oC) 3-
hydroxyphenylurethane as white solid. A 
solution of 3-hydroxyphenylurethane (7.0 g) 
and substituted ethyl acetoacetate (1.2 
equivalent) suspended in 88 mL of 70% 
ethanolic H2SO4 was stirred at room 
temperature for 4-6 h. On completion of the 
reaction the clear yellow solution was 
285 
ISSN: 2249 –4820 
Chemistry & Biology Interface, 2011, 1, 2, 279-296 
 
poured into 400 mL of ice cold water, 
giving a voluminous brown crystalline 
precipitate. The solid was filtered and then 
crystallized from ethanol to give 
carbethoxy/urethane protected 
aminocoumarin. The protected 
aminocoumarin (5.0 g) were refluxed for 4 h 
in a mixture of concentrated H2SO4 and 
glacial acetic acid (1:1, 10 ml). On cooling a 
yellow precipitate was deposited. The 
mixture was poured over 100 mL of ice cold 
water and allowed to stand overnight. The 
resulting suspension was made slightly 
alkaline with 50% aqueous NaOH under 
cold conditions. The brown precipitate 
formed was then filtered and washed with 
ice cold water (3 × 50 mL). Crystallization 
from ethanol yielded light brown colored 
crystals to give 7-amino coumarin (30-34). 
 
7-Amino-3-hexyl-4-methylcoumarin (32). 
Melting point = 198-200 oC; UV 
(acetonitrile) λmax: 348 nm; IR (KBr) νmax: 
3447.78, 3356.61 (NH2), 1678.16 (COO) 
cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 
0.81 (brs, 3H, -CH2(CH2)4CH3), 1.23-1.34 
(m, 8H, -CH2(CH2)4CH3), 2.24 (s, 3H, C-4 
CH3), 2.42 (brs, 2H, -CH2(CH2)4CH3), 5.90 
(brs, 2H, NH2), 6.34 (s, 1H, H-8), 6.51 (d, 
1H, J = 8.4 Hz, H-6), 7.36 (d, 1H, J = 8.4 
Hz, H-5); 13C NMR (DMSO-d6, 100.6 
MHz): δ 14.49 and 14.88 (-CH2(CH2)4CH3 
and C-4 CH3), 22.62, 27.19, 28.97, 29.21, 
31.69 (-(CH2)5CH3), 98.94 (C-8), 109.96 
and 111.75 (C-6 and C-10), 119.34 (C-3), 
126.51 (C-5), 147.80 (C-4), 152.45 and 
154.32 (C-7 and C-9), 161.90 (C-2); HRMS: 
Calculated for C16H21NO2 [M + H]+ 
260.1572, found 260.1652. 
 
7-Amino-3-decyl-4-methylcoumarin (33). 
Melting point = 172-174 oC; UV 
(acetonitrile) λmax: 339 nm; IR (KBr) νmax: 
3451.51, 3358.51 (NH2), 1676.82 (COO) 
cm-1; 1H NMR (DMSO-d6, 300 MHz): δ 
0.85 (brs, 3H, -CH2(CH2)8CH3), 1.23-1.39 
(m, 16H, -CH2(CH2)8CH3), 2.28 (s, 3H, C-4 
CH3), 2.45-2.47 (m, 2H, -CH2(CH2)8CH3), 
5.93 (brs, 2H, NH2), 6.39 (s, 1H, H-8), 6.56 
(d, 1H, J = 8.4 Hz, H-6), 7.40 (d, 1H, J = 8.4 
Hz, H-5); 13C NMR (DMSO-d6, 75.5 MHz): 
δ 13.86 and 14.27 (-CH2(CH2)8CH3 and C-4 
CH3), 22.02, 22.02, 26.58, 28.37, 28.63, 
28.84, 28.92, 28.92, 31.22 (-(CH2)9CH3), 
98.39 (C-8), 109.41 and 111.17 (C-6 and C-
10), 118.80 (C-3), 126.89 (C-5), 147.17 (C-
4), 151.85 and 153.74 (C-7 and C-9), 161.37 
(C-2); HRMS: Calculated for C20H29NO2 [M 
+ Na]+ 338.2096, found 338.2071. 
 
General procedure of synthesis of 4-N-
aminoalkylamino-2H-1-benzopyran-2-
ones (35-40). 4-Chlorocoumarin (1.0 g) and 
t-butyl aminoalkylcarbamate (1 equivalent) 
were taken in a round bottom flask along 
with 20 ml of ethanol. The mixture was 
refluxed for 4 hrs and the progress of 
reaction was monitored on TLC (5% 
methanol-chloroform). On completion of the 
reaction the solvent was evaporated under 
reduced pressure. Water (50 ml) was added 
to the crude mixture followed by extraction 
with methylene chloride. The organic layer 
was then dried over anhydrous sodium 
sulfate and evaporated under reduced 
pressure. The residue obtained was 
crystallized in chloroform-petroleum ether 
(1:10) to give Boc protected 4-N-
alkylaminocoumarin. Deprotection of the 
Boc group was carried out by treating the 
coumarin carbamate with a mixture of 
TFA/DCM (1:1, 2 ml) at room temperature. 
The progress of the reaction was monitored 
on TLC (10% methanol-chloroform). On 
completion of deprotection the solvent was 
evaporated under reduced pressure. Further 
the residue was treated with sodium 
hydroxide solution (1N) to neutralize the 
excess of trifluoroacetic acid and to generate 
a free amino group. This was followed by 
extraction with dichloromethane. The 
organic phase was dried over anhydrous 
sodium sulfate and evaporated under 
reduced pressure. The residue obtained was 
crystallized in methanol to give the 
corresponding unprotected analogs of 4-N-
alkylaminobenzopyran-2-one.  
 
4-(2-Amino-ethylamino)-2H-1-
benzopyran-2-one (35). Melting point = 
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223 oC; UV (acetonitrile) λmax: 290 and 308 
nm; IR (KBr) νmax: 3347, 3291 (NH), 1694 
(CO) cm-1; 1H NMR (DMSO-d6, 300 MHz): 
δ 2.06 (brs, 2H, NH2), 2.48 (brs, 2H, H-2′), 
2.77-2.79 (m, 2H, H-1′), 5.17 (s, 1H, H-3), 
7.26-7.29 (m, 2H, H-6 and H-8), 7.56 (t, 1H, 
J = 7.0 Hz, H-7), 8.05 (d, 1H, J = 7.5 Hz, H-
5); 13C NMR (DMSO-d6, 75.5 MHz): δ 
40.26 and 45.68 (C-1′ and C-2′), 81.22 (C-
3), 114.43 and 116.89 (C-8 and C-10), 
122.47 and 123.20 (C-5 and C-6), 131.82 
(C-7), 153.01 and 153.33 (C-4 and C-9), 
161.61 (C-2); HRMS: Calculated for 
C11H12N2O2 [M + H]+ 205.0932, found 
205.1016. 
 
4-(4-Amino-butylamino)-2H-1-
benzopyran-2-one (36). Melting point = 
156 oC; UV (acetonitrile) λmax: 288 and 310 
nm; IR (KBr) νmax: 3383, 3346 (NH), 1671 
(CO) cm-1; 1H NMR (DMSO-d6, 300 MHz): 
δ 1.65 (brm, 4H, H-2′ and H-3′), 3.00-3.04 
(m, 2H, H-4′), 3.28-3.30 (m, 2H, H-1′), 5.20 
(s, 1H, H-3), 7.30-7.35 (m, 2H, H-6 and H-
8), 7.59 (t, 1H, J = 7.4 Hz, H-7), 7.71-7.73 
(brm, 3H, NH and NH2),  8.05 (d, 1H, J = 
8.1 Hz, H-5); 13C NMR (DMSO-d6, 75.5 
MHz): δ 24.06 and 24.72 (C-2′ and C-3′), 
38.60 and 41.61 (C-1′ and C-4′), 81.42 (C-
3), 114.48 and 116.98 (C-8 and C-10), 
122.45 and 123.28 (C-5 and C-6), 131.91 
(C-7), 153.12 and 158.61 (C-4 and C-9), 
161.62 (C-2); HRMS: Calculated for 
C13H16N2O2 [M]+. 232.1212, found 
232.1290. 
 
4-(2-Amino-ethylamino)-6-methyl-2H-1-
benzopyran-2-one (37). Melting point = 
212 oC at atmospheric pressure. (Literature 
value = 192-194 oC at 0.5 torr) [22]; UV 
(acetonitrile) λmax: 291, 312 and 322; IR 
(KBr) νmax: 3364, 3325 (NH), 1675 (CO) 
cm-1; 1H NMR (DMSO-d6, 300 MHz): δ 
1.89 (brm, 2H, H-2′), 2.36 (s, 3H, CH3), 
2.91 (brm, 2H, H-1′), 5.20 (s, 1H, H-3), 7.20 
(d, 1H, J = 8.1 Hz, H-8), 7.40 (d, 1H, J = 7.8 
Hz, H-7), 7.66 (brs, 1H, NH), 7.83 (brs, 3H, 
H-5 and NH2); 13C NMR (DMSO-d6, 100.6 
MHz): δ 20.95 (CH3), 38.70 and 41.10 (C-1′ 
and C-2′), 83.23 (C-3), 115.26 and 118.14 
(C-8 and H-10), 122.95 (C-7), 134.43 and 
135.24 (C-5 and C-6), 152.66 and 156.04 
(C-4 and C-9), 166.32 (C-2); HRMS: 
Calculated for C12H14N2O2 [M]+. 218.2518, 
found 218.2734. 
 
4-(4-Amino-butylamino)-6-methyl-2H-1-
benzopyran-2-one (38), Melting point = 
175 oC; UV (acetonitrile) λmax: 292, 308 and 
322 nm; IR (KBr) νmax: 3348, 3310 (NH), 
1671 (CO) cm-1; 1H NMR (DMSO-d6, 300 
MHz): δ 1.66 (brm, 4H, H-2′ and H-3′), 2.35 
(s, 3H, CH3), 2.84 (brm, 2H, H-4′), 3.26 
(brm, 2H, H-1′), 5.14 (s, 1H, H-3), 7.17 (d, 
1H, J = 7.5 Hz, H-8), 7.38 (d, 1H, J = 7.2 
Hz, H-7), 7.66 (brs, 1H, NH),  7.88 (brs, 
3H, H-5 and NH2); 13C NMR (DMSO-d6, 
100.6 MHz): δ 25.54 (CH3), 26.02 and 
27.17 (C-2′ and C-3′), 40.41 and 43.16 (C-1′ 
and C-4′), 81.98 (C-3), 115.79 and 118.47 
(C-8 and C-10), 122.99 and 125.16 (C-5 and 
C-7), 133.39 (C-6), 154.60 and 156.10 (C-4 
and C-9), 166.42 (C-2); HRMS: Calculated 
for C14H18N2O2 [M - H]+ 245.1368, found 
245.1410. 
 
General procedure for the synthesis of 4-
(3-(N3,N3-dialkylamino)propylamino)-2H-
1-benzopyran-2-ones (39-40). 4-Chloro-
2H-1-benzopyran-2-one (1.0 g, 5 mmol) and 
N3, N3-dialkylpropane-1,3-diamine were 
mixed in 1:2 ratio in a round bottom flask 
along with 20 ml of ethanol. The mixture 
was refluxed for 4 h and the progress of 
reaction was monitored on TLC. On 
completion of the reaction the solvent was 
evaporated under reduced pressure. Water 
(15 ml) was added to the crude mixture 
followed by extraction with 
dichloromethane (3 x 10 ml). Then, the 
organic layer was dried over anhydrous 
sodium sulfate and evaporated under 
reduced pressure. The residue obtained was 
crystallized in chloroform-petroleum ether 
(1:10) to give the 4-N,N-
dialkylaminobenzopyran-2-one (39−40). 
 
4-(3-(N3,N3-Dimethylamino) propylamino)-
2H-1-benzopyran-2-one (39). Melting point = 
84-85 oC.; UV (acetonitrile) λmax: 293 and 
287 
ISSN: 2249 –4820 
Chemistry & Biology Interface, 2011, 1, 2, 279-296 
 
308 nm; IR (KBr) νmax: 3343 (NH), 2926, 
2827, 1669 (CO) cm-1; 1H NMR (DMSO-d6, 
300 MHz): δ 1.72-1.76 (m, 2H, H-2′), 2.14 
(s, 6H, 2 x CH3), 2.30 (t, 2H, J = 6.5 Hz, H-
3′), 3.24-3.28 (m, 2H, H-1′), 5.12 (s, 1H, H-
3), 7.27-7.32 (m, 2H, H-6 and H-8), 7.54-
7.56 (m, 1H, H-7), 7.93 (brs, 1H, NH),  7.94 
(d, 1H, J = 7.5 Hz, H-5); 13C NMR (DMSO-
d6, 75.5 MHz): δ 23.60 (C-2′), 44.23 (C-3′), 
45.35 (2 x CH3), 59.46 (C-1′), 82.25 (C-3), 
115.11 and 117.77 (C-8 and C-10), 120.72 
and 123.31 (C-5 and C-6), 131.36 (C-7), 
153.71 and 153.71 (C-4 and C-9), 163.51 
(C-2); HRMS: Calculated for C14H18N2O2 
[M]+. 246.1368, found 246.2602. 
 
4-(3-(N3,N3-Diethylamino)propylamino)-
2H-1-benzopyran-2-one (40). Melting 
point = 99-100 oC; UV (acetonitrile) λmax: 
293 and 308 nm; IR (KBr) νmax: 3326 (NH), 
1702 (CO) cm-1; 1H NMR (DMSO-d6, 300 
MHz): δ 0.96 (t, 6H, J = 7.0 Hz, 2 x 
CH2CH3), 1.72-1.77 (m, 2H, H-2′), 2.45-
2.52 (m, 6H, H-3′ and 2 x CH2CH3), 3.26-
3.28 (m, 2H, H-1′), 5.14 (s, 1H, H-3), 7.29-
7.34 (m, 2H, H-6 and H-8), 7.56-7.58 (m, 
1H, H-7), 7.88 (brs, 1H, NH),  7.95 (d, 1H, 
J = 8.1 Hz, H-5); 13C NMR (DMSO-d6, 75.5 
MHz): δ 11.36 (2 x CH2CH3), 23.55 (C-2′), 
44.66 (C-3′), 46.99 (2 x CH2CH3), 53.49 (C-
1′), 82.23 (C-3), 115.02 and 117.80 (C-8 and 
C-10), 121.10 and 122.98 (C-5 and C-6), 
131.35 (C-7), 153.58 and 153.70 (C-4 and 
C-9), 163.49 (C-2); HRMS: Calculated for 
C16H22N2O2 [M + H]+ 275.1715, found 
275.1691. 
Pharmacology 
 
Cell culture. Human ovarian 
adenocarcinoma cell line SKOV3 (ATCC 
no. HTB-77), human breast carcinoma 
MCF-7 (ATCC no. HTB-22), human breast 
carcinomaMDA-MB-468 (ATCC no. HTB-
27), and human colon adenocarcinoma HT-
29 (ATCC no. HTB-38) were obtained from 
American Type Culture Collection. The 
cells were grown on 75 cm2 cell culture 
flasks with EMEM (Eagle’s minimum 
essential medium), supplemented with 10% 
fetal bovine serum, and 1% 
penicillin/streptomycin solution (10,000 
units of penicillin and 10 mg of 
streptomycin in 0.9% NaCl) in a humidified 
atmosphere of 5% CO2, 95% air at 37 ºC. 
 
Cell proliferation assay. Cell proliferation 
assay was carried out using Cell Titer 96 
aqueous one solution cell proliferation assay 
kit (Promega, USA) as described previously 
[8,9]. Briefly, upon reaching about 75-80% 
confluency, 5000 cells/well were plated in 
96-well microplate in 100 µL media. After 
seeding for 72 h, the cells were treated with 
50 µM compound in triplicate. Doxorubicin 
(10 µM) was used as the positive control. At 
the end of the sample exposure period (72 
h), 20 µL Cell Titer 96 aqueous solution was 
added. The plate was returned to the 
incubator for 1 h in a humidified atmosphere 
at 37 °c. The absorbance of the formazan 
product was measured at 490 nm using a 
microplate reader. The blank control was 
recorded by measuring the absorbance at 
490 nm with wells containing medium 
mixed with Cell Titer 96 aqueous solution 
but no cells. Results were expressed as the 
percentage of the control (without 
compound set at 100%). 
 
c-Src kinase activity assay. The effect of 
synthesized compounds on the activity of c-
Src kinase was assessed by Transcreener® 
ADP2 FI Assay, from Bell Brook Labs, 
Madison, WI, (catalogue no. 3013-1K) 
according to manufacturer’s protocol as 
described previously [8,9,19]. 384-well Low 
volume Black non-binding surface round 
bottom microplate was purchased from 
Corning (#3676). In summary, the kinase 
reaction was started in 384-well low volume 
black microplate with the incubation of the 
2.5 µL of the reaction cocktail (0.7 nM of 
His6-Src kinase domain in kinase buffer) 
with 2.5 µL of prediluted compounds 
(dissolved in 10% DMSO, 4X target 
concentration) for 10 min at room 
temperature using microplate shaker. The 
reaction cocktail was made using the kinase 
buffer HEPES (200 mM, pH 7.5), MgCl2 
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(16 mM), EGTA (8 mM), DMSO (4%), 
Brij-35 (0.04%), and 2-mercaptoethanol (43 
mM). Kinase reaction was started by adding 
5 µL of ATP/substrate (40 µM/600µM) 
cocktail and incubated for 30 min at room 
temperature on microplate shaker. Src 
optimal peptide (AEEEIYGEFEAKKKK) 
was used as the substrate for the kinase 
reaction. The kinase reaction was stopped 
by adding 10 µL of the 1X ADP Detection 
Mixture to the enzyme reaction mixture and 
mixed using a plate shaker. The mixture was 
incubated at room temperature for 1 h, and 
the fluorescence intensity was measured. 
The 1X ADP Detection Mixture was 
prepared by adding ADP2 Antibody-
IRDyeR QC-1 (10 µg/mL) and ADP 
Alexa594 Tracer (8 nM) to Stop and Detect 
Buffer B(1X). Fluorescence Intensity 
measurements were performed using 
fluorescence intensity optical module using 
the excitation of 580 nm and emission of 
630 nm with band widths of 10 nm by 
Optima, BMG Labtech microplate reader. 
IC50 of the compounds were calculated 
using ORIGIN 6.0 (origin lab) software. 
IC50 is the concentration of the compound 
that inhibited enzyme activity by 50%. All 
the experiments were carried out in 
triplicate. 
 
Results and Discussion 
 
Chemistry 
 
Six classes of coumarin derivatives (i.e. C-3 
alkylated-4-methylcoumarins, 
pyranocoumarins, coumarin carboxamides, 
quaternary ammonium coumarins, 7-
aminocoumarins, and 4-aminocoumarins) 
were synthesized. 
 
Synthesis of C-3 alkyl-4-methylcoumarins 
Scheme 1 shows the synthesis of C-3 alkyl-
4-methylcoumarins (Class I). 7-Hydroxy-4-
methylcoumarins (1 and 2) and 7,8-
dihydroxy-4-methylcoumarins (3-5) were 
synthesized in quantitative yields by 
Pechmann condensation of resorcinol or 
pyrogallol with alkylated ethyl acetoacetates 
in the presence of sulphuric acid. Synthesis 
of alkylated β-ketoester in turn was carried 
out according to the earlier published 
procedure from our group [23,24]. 
 
Synthesis of pyranocoumarins 
 
The synthesis of pyranocoumarins (Class II) 
is shown in Scheme 2. Nuclear prenylation 
of 3-alkyl-7,8-dihydroxy-4-
methylcoumarins was carried out using 2-
methyl-3-buten-2-ol in the presence of p-
toluene sulfonic acid monohydrate 
(PTSA.H2O) in toluene, which undergoes in 
situ cyclization to afford corresponding 
pyranocoumarin in a moderate yield (35%) 
(Scheme 2).  
 
Synthesis of coumarin carboxamides 
 
Coumarin carboxamides (Class III) were 
synthesized starting from 3-substituted 
carboxycoumarins (11,12), which were in 
turn prepared from salicylaldehydes and 
Meldrum’s acid via Knovaenegel reaction 
[25]. However, 3-carboxy-4-
methylcoumarin 13 was synthesized 
according to the previously reported 
procedure [26]. 
 
Coumarin-3-carboxamides (14−17) were 
obtained via coupling of 3-carboxycoumarin 
with methyl 2-amino alkanoates in the 
presence of ethyl chloroformate and 
triethlyamine in acetone (Scheme 3). Methyl 
2-amino alkanoates were in turn synthesized 
by esterification of various amino acids 
using thionyl chloride and methanol [27,28]. 
In another route, coumarin carboxamides 
(18-21) having diamino alkyl groups were 
synthesized by amidation of 3-
carboxycoumarins with mono-Boc protected 
diamino alkanes using BOP as a coupling 
agent. Finally, deprotection of the Boc 
group using a mixture of trifluoroacetic acid 
(TFA)/dichloromethane (DCM) gave the 
corresponding coumarin carboxamides 
(18−21, Scheme 3). The mono-Boc 
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protected diamino alkanes were synthesized 
by the reaction of the corresponding daimio 
alkane with di-tertbutyl dicarbonate 
((Boc)2O) (0.12 equivalent) [29-31]. 
 
Synthesis of quaternary ammonium 
coumarin derivatives 
 
The quaternary ammonium ester (22-25) 
and ether (26-29) derivatives of coumarins 
(Class IV) were synthesized as shown in 
Schemes 4 and 5. The physical and spectral 
data (1H, 13C NMR, UV, IR, HRMS) for this 
class of compounds have already been 
reported [32]. 
 
Synthesis of 7-aminocoumarins 
 
7-Aminocoumarins, the Class V compounds 
i.e. C-3 unsubstituted/C-3 alkyl substituted 
7-amino-4-methylcoumarins (30-33) and 7-
amino-4-trifluoromethylcoumarin (34) were 
synthesized as per literature method [33] 
and characterized completely. First, the 
urethane protected m-aminophenol (3-
hydroxyphenylurethane) was prepared to 
react with alkylated ethyl acetoacetate or 
4,4,4-trifluoro ethyl acetoacetate in the 
presence of 70% H2SO4-C2H5OH to obtain 
3-alkyl-7-carbethoxy-4-methyl/ 
trifluoromethyl  coumarin quantitatively via 
Pechmann condensation. The deprotection 
of corresponding 7-carbethoxy-4-methyl/ 
trifluoromethyl coumarins was then carried 
out with a mixture of sulphuric acid and 
acetic acid (1:1) to yield 3-alkyl-7-
aminocoumarins (30-34, Scheme 6). 
 
Synthesis of 4-aminocoumarin derivatives 
 
The synthesis of 4-aminocoumarin 
derivatives (35−40, Class VI) is outlined in 
Scheme 7. They were synthesized in two 
steps i.e. first the 4-chlorocoumarins were 
treated with mono-Boc protected diamino 
alkanes in ethanol. In the next step, 
deprotection of the Boc group using a 
mixture of TFA / DCM gave the 
corresponding 4-N-alkylaminocoumarins 
(35-40, Scheme 7). The 4-N,N-
dialkylaminocoumarins (39-40, Scheme 7), 
on the other hand were synthesized by 
coupling of 4-chlorocoumarin with N,N-
dialkylpropane-1,3-diamine. 
 
Biological Activity 
 
Antiproliferative activities 
 
The effect of forty diversely substituted 
coumarins from six classes was evaluated on 
the cell proliferation of cancer cells, colon 
adenocarcinoma (HT-29), breast carcinoma 
(MDA-MB-468/MCF-7), and human 
ovarian adenocarcinoma (SK-OV-3) cells, at 
the concentration of 50 µM (Figure 2). 
Compounds 10 and 29 showed modest 
antiproliferative activity (63-72%) against 
HT-29 and SK-OV-3 cells. Furthermore, 
compounds 5 and 6 inhibited the cell 
proliferation of MDA-MB-468 and SK-OV-
3 cells by 53-74%. 
 
On further analyzing the effect of these 
compounds on proliferation of cancer cells, 
it was observed that the proliferation activity 
gets reduced by incorporating the chroman 
ring, i.e. the pyranocoumarins 7 and 9 were 
generally less active than their hydroxyl-
substituted precursors 3 and 4. However, in 
chromano coumarins the substitutions of 
smaller (C2) and larger (C9/C10) alkyl chains 
at C-3 position exhibited better cell 
proliferation inhibitory activity as compared 
to compounds having intermediate size alkyl 
chains. 
 
The substitution of C-3 alkyl group by 
carboxylic group in coumarins 11 and 13 
drastically reduced the activity. The C-3 
carboxy coumarin 13 containing a methyl 
group at the C-4 position was less active 
than the C-3 alkyl 4-methylcoumarins (1-5). 
However, the conversion of carboxylic to 
amidic linkage in compounds 14 and 16 
slightly improved the antiproliferative 
activity against HT-29 cells in comparison 
with compounds 11 and 13. The amino acid 
conjugates (14, 16, and 17) also exhibited 
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better activity as compared to amides 
formed from diamino alkanes (18-21) 
against HT-29 and MDA-MB-468/MCF 
cells. A comparison of quaternary amino 
acyloxy (22-25) and alkoxy (28 and 29) 
coumarin derivatives revealed that the latter 
are more active against all cells and the 
activity enhances with increase in 
hydrophobicity of compounds. Among the 
aminocoumarin derivatives, 7-amino-4-
methylcoumarins (31 and 32) showed 
slightly better activity in comparison to the 
4-aminocoumarin derivatives 35-40 against 
HT-29 and SK-OV-3 cells.  
 
Src kinase inhibitory activities 
 
The mechanism of antiproliferative 
activities of these compounds is currently 
under investigation. HT-29, SK-OV-3, and 
MDA-MB-468 cell lines express highly 
activated Src [34,35]. Thus, preliminary 
studies were carried out to investigate the 
inhibitory activities of forty diversely 
substituted coumarins from six classes 
against Src kinase. Table 1 shows the 
inhibitory potency of the synthesized 
compounds compared to a general protein 
kinase inhibitor, staurosporine, and a Src 
kinase inhibitor, PP2. In general, most of the 
coumarin derivatives were weak Src kinase 
inhibitors (IC50 > 150 µM). The data suggest 
that among all the coumarin derivatives the 
C-3 alkyl-substituted coumarins showed 
improved activity in comparison to the 
unsubstituted analogs. Also it has been 
observed that among all the compounds, the 
quaternary ammonium derivatives 
substituted at C-3 position with hexyl or 
decyl chains (24 and 25), exhibited higher 
Src inhibitory activity (IC50 = 21.6-36.0 
µM). 7-Aminocoumarins 33 and 34 also 
showed modest Src kinase inhibition (IC50 = 
30.9-73.9 µM).  
 
From the enzyme inhibition studies, it can 
be inferred that there was poor correlation 
between Src kinase inhibitory potency and 
the growth inhibition of cancer cells. 
Compounds 10 and 29 showed modest 
antiproliferative activity (63-72%) against 
HT-29 and SK-OV-3 cells. Furthermore, 
compounds 5 and 6 inhibited the cell 
proliferation of MDA-MB-468 and SK-OV-
3 cells by 53-74%. However, these 
compounds did not exhibit any significant 
Src kinase inhibition. On the other hand, 
compounds with modest Src kinase 
inhibitory activities, such as 25, 
demonstrated weak antiproliferative 
activities. The data suggest that other 
mechanisms may be involved in the 
relatively modest antiproliferative activities 
of these compounds. Various substituted 4-
aryl-4H-chromen-3-carbonitrile have 
previously reported to exhibit 
antiproliferative activities through 
apoptosis-inducing effect [36-38]. It remains 
to be investigated whether the active 
compounds in these six classes of coumarin 
derivatives have any apoptosis effect.  
 
Conclusions 
 
In summary, six classes of coumarin 
derivatives including fourteen novel 
compounds (6-10, 19-21, 32-33, 35-36, 38 
and 40) were synthesized and fully 
characterized by 1H, 13C NMR, UV, IR, and 
high resolution mass spectroscopy (HRMS). 
The spectral data for all the novel 
compounds and those that are not previously 
reported (14-18, 37 and 39) is given as 
supplementary material. 
 
The coumarin derivatives were evaluated for 
Src kinase inhibitory and antiproliferative 
activities. To the best of our knowledge, this 
is the first report of the evaluation of these 
six classes of coumarin derivatives as Src 
kinase inhibitors. Structure-activity 
relationships revealed that a number of C-3 
alkyl-substituted quaternary ammonium (24 
and 25) and 7-aminocoumarins (33 and 34) 
showed modest Src kinase inhibitor 
activities. Among all compounds, C-3 alkyl-
substituted pyranocoumarins 6 and 10 
exhibited 63-74% antiproliferative activity 
in SK-OV-3 cells. A structure activity 
relationship for coumarin derivatives in 
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terms of Src kinase inhibitory and 
antiproliferative activities has been reported. 
Further studies are underway for structural 
optimization of C-3 alkyl-substituted 
coumarin derivatives to generate compounds 
with more potential antiproliferative 
activities. 
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 Chemical structures of six classes of synthesized coumarin derivatives: I: C-3 alkylated-4-
methylcoumarins; II: pyranocoumarins; III: coumarin carboxamides; IV: quaternary ammonium 
coumarins; V: 7-aminocoumarins; and VI: 4-aminocoumarin derivatives. 
 
Figure 1. 
 
Scheme 1. Synthesis of C-3 alkylated-4-methylcoumarins: i. NaH, RBr, THF; ii. 
resorcinol/pyrogallol, H2SO4. 
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Scheme 2. Synthesis of pyranocoumarins. i. 2-methyl-3-buten-2-ol, P-TSA.H2O, toluene, reflux. 
 
Scheme 3. Synthesis of coumarin carboxamides: i. Ethyl chloroformate, Et3N, 
NH2CH(R″)COOMe, acetone, 37 °C; ii. Ethyl chloroformate, Et3N, NH2(CH2)2COOMe, acetone, 
37 °C; iii. BocNHCH2(CH2)nNH2, BOP reagent, CH3CN, Et3N, DCM, 37 °C; iv. TFA-DCM (1:1), 
37 °C. 
 
Scheme 4. Synthesis of quaternary ammonium coumarin derivatives: i. Br(CH2)10COCl, Et3N (1 
equiv.), CH3CN, 37 °C; ii. Et3N (5 equivalent), CH3CN, 60 °C, 96 h. 
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Scheme 5. Synthesis of quaternary ammonium derivatives: i. XCH2(CH2)mCH2X, K2CO3, acetone; 
ii. Et3N/Bu3N (5 equivalent), CH3CN, 60 °C. 
 
Scheme 6. Synthesis of 7-aminocoumarins: i. C2H5OCOCl, Et2O, 37 oC; ii. R'COCHRCOOC2H5, 
H2SO4-C2H5OH (7:3), 37 oC; iii. H2SO4-CH3COOH (1:1), reflux. 
 
Scheme 7. Synthesis of 4-aminocoumarin derivatives: i. BocNHCH2(CH2)nNH2, ethanol; ii. TFA-
DCM (1:1), 25 °C; iii. R'2NCH2CH2CH2NH2, ethanol. 
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*Compound (8, 10-11, 13-17, 21-29, 34, 37, and 39) were tested against breast carcinoma MCF-7 
cell line. 
Figure 2. Cell proliferation of HT-29, MDA-MB-468/ MCF-7*, and SK-OV-3 cell lines by 
coumarin derivatives. 
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Table 1. Src kinase inhibitory activity of coumarin derivatives (1-40).  
Compound IC50 (µM)a Compound IC50 (µM)a 
1 > 300 23 > 300 
2 > 300 24 36.0 
3 90.4 25 21.6 
4 > 300 26 > 300 
5 > 300 27 > 300 
6 > 300 28 > 300 
7 > 300 29 > 300 
8 87.8 30 78.5 
9 > 300 31 > 300 
10 > 150 32 > 300 
11 > 300 33 73.9 
13 > 150 34 30.9 
14 > 300 35 > 300 
15 > 300 36 > 300 
16 > 300 37 > 300 
17 > 300 38 > 300 
18 > 300 39 > 300 
19 > 300 40 > 250 
20 > 300 Staurosporine 0.6 
21 > 300 PP2 0.5 
22 62.6   
aThe concentration at which the enzyme activity is inhibited by 50%.
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